COLL
COLLEGIUM PHARMACEUTICAL, INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 ▲ Collegium Pharmaceutical reported strong financial results for Q4 an…
- Mar 3 to Mar 9 ▼ 2 days of insider sells: $2.2M by 2 insiders, avg $39.99
- Mar 18 ▼ 1 insider sell $488.1K at $34.92
- Mar 19 ▲ Collegium Pharmaceutical is acquiring AZSTARYS, a differentiated ADH…
- May 11 to May 18 ▼ 4 days of insider sells: $628.6K by 3 insiders, avg $36.24
- May 12 ▲ Collegium Pharmaceutical completed the acquisition of AZSTARYS, an A…
- Jun 5 Contract: Collegium Pharmaceutical Reports Inducement Grants Under N…
- Aug 6 Collegium reported Q2 2026 adjusted EPS of $1.92, beating the Street…
- Aug 14 ▼ Short interest jumps 28.4% to 6.52M
- Aug 19 Walgreen Co. v. Collegium Pharmaceutical, Inc.
- Sep 23 Oppenheimer initiates
- Oct 29 Contract: Collegium Pharmaceutical and Boston Legacy FC Expand Their…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $3.4M.
- InstitutionsMIXED
Q3 2026: 27 added (0 new), 28 trimmed or exited.
- AnalystsBULLISH
12 of 14 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −3.4% to 5.19M shares. 9.4 days to cover, ≈16.7% of shares.
- TrendUPTREND
10% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Invesco Ltd. | TRIM | $27.5M |
| AMERICAN CENTURY COMPANIES INC | ADD | $14.0M |
| FULLER & THALER ASSET MANAGEMENT, INC. | TRIM | $13.1M |
| ROYCE & ASSOCIATES LP | TRIM | $4.9M |
| FIRST TRUST ADVISORS LP | ADD | $4.9M |
| SEI INVESTMENTS CO | ADD | $3.7M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | TRIM | $2.4M |
| Creative Planning | DOUBLED | $2.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +75%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 6, 2026 | Piper Sandler MAINTAIN | Neutral |
| Nov 5, 2026 | Needham MAINTAIN | Buy |
| Sep 23, 2026 | Oppenheimer INITIATE | Outperform |
| Sep 9, 2026 | Truist Securities MAINTAIN | Buy |
| Sep 9, 2026 | Leerink Partners INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
SANTINI GINO Director Jun 8, 2026 | EXERCISE | $143.5K |
Freund John Gordon Director May 18, 2026 | SELL | $681.00 |
Freund John Gordon Director May 15, 2026 | EXERCISE | $143.5K |
Freund John Gordon Director May 15, 2026 | SELL | $142.5K |
Freund John Gordon Director May 14, 2026 | AWARD | 8,741 sh |
Glancy Donovan Michael Director May 14, 2026 | AWARD | 17,482 sh |
SANTINI GINO Director May 14, 2026 | AWARD | 8,741 sh |
Lurker Nancy Director May 14, 2026 | AWARD | 8,741 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 4 press releases · 2 bullish · 2 bearish · 3 mixed · 13 neutral- NEUTRAL SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G disclosing a passive stake of 64,540 shares (0.2%) in Collegium Pharmaceutical as of September 30, 2026. This is a minimal position, down from a prior 5%+ stake, continuing the pattern of institutional exits from Collegium.
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 10, 2026
Invesco Ltd. filed an amended Schedule 13G disclosing a 3.9% passive stake in Collegium…
Invesco's reduction below 5% adds to a pattern of institutional exits from Collegium, with three major filers (Vanguard, Principal, Invesco) all reporting sub-5% stakes in recent weeks. Monitor next…
- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a Schedule 13G disclosing a 5.4% passive stake in Collegium Pharmaceutical…
State Street's passive stake disclosure adds to a mixed institutional picture: Millennium Management increased to 7.4% (Oct 8 filing) while Vanguard and Principal Global Investors reduced below 5%…
- BEARISH INST-CLUSTERNov 9, 2026
Institutional activity in COLLEGIUM PHARMACEUTICAL during Q3 2026 was mixed: 4 small buyers added…
The 20:1 ratio of selling to buying, combined with a full exit by a top-5 holder (Assenagon) and no insider buying, signals institutional loss of conviction. Monitor next 10-Q for further position…
All COLL filing & press-release reports (24)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 10, 2026
- SC 13G reportNov 10, 2026
- INST-CLUSTER reportNov 9, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- SC 13G/A reportOct 30, 2026
- SC 13G/A reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- PRESS-RELEASE reportOct 22, 2026
- 8-K reportOct 19, 2026
- SC 13G/A reportOct 8, 2026
- COURT-RULING reportAug 19, 2026
- 8-K reportAug 13, 2026
- 8-K reportAug 6, 2026
- CLUSTER reportMay 15, 2026
- PRESS-RELEASE reportMay 12, 2026
- 144 reportMay 11, 2026
- PRESS-RELEASE reportApr 23, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportMar 3, 2026
- PRESS-RELEASE reportMar 3, 2026
- 8-K reportFeb 26, 2026